Gold Nanomedicine Clinical Trial Delivers Promising Results

Novel Approach in Cancer Therapy at the Forefront of Gold-Based Medical Applications

LONDON, December 21, 2010 - The World Gold Council (WGC) is delighted with the successful phase 1
clinical trial of a unique nanomedicine that uses nanoparticles of gold as
the core of a delivery system for tumour targeted drug delivery. The
research, published in the current edition of Clinical Cancer Research, was
carried out by US-based life sciences company CytImmune Sciences Inc.

CytImmune's technology is at the forefront of a raft of
gold-based innovations as described earlier this year by the WGC in a paper
entitled 'Gold for Good: Gold and nanotechnology in the age of innovation'.
The report demonstrates how gold nanoparticles exhibit a variety of unique
properties which are showing great potential in a range of fields.

Dr Richard Holliday, Director, Technology at the WGC said: "Gold
has a long history in the biomedical field, being the material of choice in
many diagnostic platforms and a key constituent for rheumatoid arthritis
treatment. The dawn of the 'nano-age' has further broadened the potential of
gold in biomedical applications and it is exciting to see the outcome of this
clinical trial which suggests that gold can act as an effective and safe drug
delivery system."

In medicine, gold nanoparticles can serve as a simple, elegant
platform upon which potent therapies may be bound. In this clinical trial the
nanoparticles, which were coated with both an immune-avoiding molecule and a
potent anti-cancer agent, were shown to be very well tolerated and to target
solid tumours. There is hope that such targeting technology will be effective
against a range of cancers, including lung, pancreatic, breast and ovarian
cancer.

Dr Lawrence Tamarkin, CEO of CytImmune Sciences Inc. said: "This phase 1
clinical study potentially marks the beginning of a new strategy in cancer
treatment where gold nanoparticle-based cancer therapeutics are used first,
before surgery, to reduce tumour burden. Reducing tumour size may require
less sophisticated surgeries to remove any residual tumour, leading to
shorter hospital stays and to improved patient outcomes. Phase 2 clinical
studies will prove the value of this novel drug delivery platform."

Dr Holliday continued: "By continuously reviewing and monitoring the
global research landscape in gold science and technology, we are able to
identify and, where appropriate, help accelerate the time to market key, new
technologies that have social, environmental or medical benefits."

Links:

www.gold.org/download/rs_archive/gold_and_nanotechnology_in_the_age_of_innovation.pdf
(Gold for Good white paper)

(Due to the length of this URL, it may be necessary to copy and paste
this hyperlink into your Internet browser's URL address field. Remove the
space if one exists.)

www.cytimmune.com/ (CytImmune website)

clincancerres.aacrjournals.org/content/16/24/6139.abstract (Link
to paper abstract)

Note to editors:

    World Gold Council

    The World Gold Council (WGC) is the market development
    organisation for the gold industry. Working within the
    investment, jewellery and technology sectors, as well as engaging
    in government affairs, its purpose is to provide industry
    leadership, whilst stimulating and sustaining demand for gold.

    The WGC researches and gives insight on the international gold
    markets, helping people to better understand the wealth
    preservation qualities of gold and its role in meeting the social
    and environmental needs of society.

    Based in the UK, with operations in India, the Far East, the
    Middle East, Europe and the USA, the WGC is an association whose
    members include the world's leading gold mining companies. For
    further information visit www.gold.org.

For further information please contact: Stephanie Mackrell, World Gold Council, T: +44(0)207-826-4763, E: Stephanie.mackrell at gold.org; Quintin Keanie, Capital MSL, T: +44(0)207-255-5514, E: Quintin.keanie at capitalmsl.com